14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 CANF stock ended at $2.09. This is 2.96% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 6.44% from a day low at $2.02 to a day high of $2.15.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Aug 26, 2021 $1.83 $1.89 $1.83 $1.87 72 177
Aug 25, 2021 $1.85 $1.89 $1.84 $1.85 69 120
Aug 24, 2021 $1.84 $1.87 $1.82 $1.86 261 472
Aug 23, 2021 $1.87 $1.88 $1.83 $1.87 196 574
Aug 20, 2021 $1.85 $1.89 $1.81 $1.87 69 415
Aug 19, 2021 $1.87 $1.89 $1.80 $1.86 131 317
Aug 18, 2021 $1.89 $1.92 $1.84 $1.87 221 652
Aug 17, 2021 $2.03 $2.03 $1.88 $1.89 143 681
Aug 16, 2021 $1.98 $2.02 $1.88 $1.91 430 936
Aug 13, 2021 $1.98 $1.99 $1.82 $1.94 308 974
Aug 12, 2021 $2.06 $2.07 $1.97 $1.97 350 890
Aug 11, 2021 $2.07 $2.09 $2.03 $2.08 28 154
Aug 10, 2021 $2.09 $2.11 $2.08 $2.10 110 177
Aug 09, 2021 $2.12 $2.14 $2.08 $2.14 30 924
Aug 06, 2021 $2.10 $2.14 $2.05 $2.12 63 837
Aug 05, 2021 $2.06 $2.12 $2.04 $2.12 71 163
Aug 04, 2021 $2.08 $2.12 $2.04 $2.07 81 595
Aug 03, 2021 $2.11 $2.11 $2.05 $2.08 85 460
Aug 02, 2021 $2.10 $2.10 $2.04 $2.09 75 131
Jul 30, 2021 $2.05 $2.10 $2.00 $2.00 139 447
Jul 29, 2021 $2.10 $2.10 $2.07 $2.09 29 541
Jul 28, 2021 $2.04 $2.08 $2.03 $2.07 87 133
Jul 27, 2021 $2.14 $2.14 $1.95 $2.04 190 507
Jul 26, 2021 $2.18 $2.18 $2.05 $2.11 152 578
Jul 23, 2021 $2.17 $2.18 $2.12 $2.16 111 727
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT